CMMB (Chemomab Therapeutics) Tariff Resilience Score: 7/10 (As of Jun. 28, 2026)


CMMB Chemomab Therapeutics Ltd CMMB
34 GF Score
Price $1.59
View Full Analysis

What is Chemomab Therapeutics Tariff Resilience Score?

Chemomab Therapeutics CMMB 34 Tariff Resilience Score is 7 as of Jun. 28, 2026. GuruFocus rates CMMB with a GF Score™ of 34/100. Among 1,376 Biotechnology companies, Chemomab Therapeutics ranks better than 90.41% on this metric.

Chemomab Therapeutics has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Chemomab Therapeutics has Biotech company with some exposure to tariffs on imported research materials. However, niche market and potential pricing power offer resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Chemomab Therapeutics might have Highly Resilient.

Chemomab Therapeutics  (NAS:CMMB) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Chemomab Therapeutics Tariff Resilience Score Related Terms

CMMB vs HCWB, MTVA, INTI: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Chemomab Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chemomab Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chemomab Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Chemomab Therapeutics's Tariff Resilience Score falls into.


CMMB
34GF Score
Chemomab Therapeutics Ltd CMMB
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Chemomab Therapeutics (CMMB) has a Tariff Resilience Score of 7 as of Jun. 28, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Chemomab Therapeutics ranks #132 out of 1376 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Chemomab Therapeutics' Tariff Resilience Score too high?
Chemomab Therapeutics' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Chemomab Therapeutics' value of 7 is 75% above this industry median. Based on the distribution chart, Chemomab Therapeutics ranks #132 out of 1376 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Chemomab Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Chemomab Therapeutics' Tariff Resilience Score compare to HCWB and MTVA?
According to the Biotechnology industry distribution chart, Chemomab Therapeutics ranks #132 out of 1376 companies for Tariff Resilience Score. This places Chemomab Therapeutics in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Chemomab Therapeutics' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,376 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chemomab Therapeutics's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemomab Therapeutics's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemomab Therapeutics stock overvalued right now?
Chemomab Therapeutics (CMMB) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Chemomab Therapeutics' overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Chemomab Therapeutics (CMMB), the current Tariff Resilience Score is 7 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chemomab Therapeutics Business Description

Address 10 Habarzel Street, 10th Floor, Building C, Tel Aviv, ISR, 6158101
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
34GF Score

Get the complete analysis for CMMB

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.59
Price